| abstract |
A 4-oxoimidazo(1,5-a)quinoxaline of formula (I), a 5-oxoimadazo(1,5-a)quinoxaline of formula (II), a diimidazoquinazoline of formula (III) or a pharmaceutically acceptable salt thereof, wherein R3 is (a), (b), (c), (d). The R-groups and 'Aryl' are as defined herein. The compounds are useful in the treatment of central nervous system disorders associated with the benzodiazepine receptors in a subject in need of such treatment comprising administering to the subject a therapeutically-effective amount of formula (I), (II) or (III) compound for alleviation of such disorder. Typically, the compound of formula (I), (II) or (III) is administered in the form of a pharmaceutical composition comprising a pharmaceutically-acceptable carrier or diluent. |